Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laboratory Monitoring and Measuring of Clinical Anticoagulants.

Seminars in thrombosis and hemostasis·2026
Same author

Systematic bias in point-of-care INR testing: comparative analysis of Abbott and Roche devices.

Clinical chemistry and laboratory medicine·2026
Same author

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same author

Harmonization of measurement units: mission impossible or ethical imperative?

Clinical chemistry and laboratory medicine·2026
Same author

100 Years of von Willebrand Disease: Celebrating a Significant Milestone in von Willebrand Disease Diagnostics and Management.

Seminars in thrombosis and hemostasis·2026
Same author

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026

Related Experiment Video

Updated: Jun 3, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

18.9K

Laboratory Assessment of Factor VIII Inhibitors: When Is It Required? A Perspective Informed by Local Practice.

Emmanuel J Favaloro1,2,3, Jennifer Curnow3,4, Leonardo Pasalic1,5

  • 1Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.

Journal of Clinical Medicine
|January 11, 2025
PubMed
Summary

Laboratory assessments are crucial for detecting factor VIII (FVIII) inhibitors in hemophilia A (CHA/AHA). Timely testing optimizes treatment and improves patient outcomes.

Keywords:
Bethesda assayacquired hemophilia Acongenital hemophilia Afactor VIIIinhibitors

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.3K

Related Experiment Videos

Last Updated: Jun 3, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

18.9K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.3K

Area of Science:

  • Hematology
  • Immunology
  • Clinical Diagnostics

Background:

  • Factor VIII (FVIII) inhibitors are antibodies targeting FVIII, complicating hemophilia A management.
  • Both congenital hemophilia A (CHA) and acquired hemophilia A (AHA) involve significant bleeding risks due to FVIII inhibitors.
  • Accurate assessment of inhibitor presence and level is vital for effective treatment strategies.

Purpose of the Study:

  • To highlight the critical role of laboratory assessments in evaluating factor VIII (FVIII) inhibitors.
  • To discuss the importance of inhibitor testing in managing both congenital and acquired hemophilia A.
  • To outline an approach to laboratory assessment of FVIII inhibitors.

Main Methods:

  • Utilizing laboratory assays, specifically the Bethesda assay, for inhibitor detection and quantification.
  • Considering the complexities of FVIII inhibitor kinetics in assay result interpretation.
  • Following clinical practice guidelines for ongoing monitoring of patients.

Main Results:

  • Laboratory assays are essential for identifying and measuring FVIII inhibitors.
  • Interpreting assay results requires understanding inhibitor kinetics; normal FVIII levels do not rule out inhibitors.
  • Ongoing monitoring is recommended until inhibitors are undetectable.

Conclusions:

  • Timely laboratory evaluations are fundamental for optimizing hemophilia A treatment.
  • Effective management of FVIII inhibitors through laboratory assessment improves patient outcomes and quality of life.
  • A structured approach to laboratory assessment informs clinical practice.